EMA Authorised: Vislyfa (ranibizumab) — Lupin Europe GmbH

View source ↗

Summary

The EMA has authorised Vislyfa (ranibizumab) by Lupin Europe GmbH for multiple retinal and diabetic eye diseases, expanding access to this anti-VEGF therapy in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetes Complications
• Macular Edema
• Retinal Vein Occlusion
• Wet Macular Degeneration

Drugs mentioned

• Vislyfa (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: Lupin Europe GmbH. Decision date: 15/07/2026